Common use of Clinical Study Termination Clause in Contracts

Clinical Study Termination. The Study Sponsor reserves the right to close the investigational site or terminate the study in its entirety at any time, for reasonable cause. If the clinical study is prematurely terminated or suspended by the Study Sponsor: • The Study Sponsor must: o Immediately notify the Investigator(s) and subsequently provide instructions for study termination. o Inform the Investigator and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension, as applicable. • The Investigator must: o Promptly notify the IRB of the termination or suspension and of the reasons. o Provide subjects with recommendations for post-study treatment options as needed. The Investigator may terminate a site’s participation in the study for reasonable cause.

Clinical Study Termination. The Study Sponsor study sponsor reserves the right to suspend or close the investigational site or suspend or terminate the study in its entirety at any time, for reasonable cause. If the clinical study is prematurely terminated or suspended by the Study Sponsorstudy sponsor: • The Study Sponsor study sponsor must: o Immediately notify the Investigator(sinvestigator(s) and subsequently provide instructions for study termination. o Inform the Investigator investigator and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension, as applicable. • The Investigator investigator must: o Promptly notify the IRB IRB/IEC of the termination or suspension and of the reasons. o Provide subjects with recommendations for post-study poststudy treatment options as needed. The Investigator investigator may terminate a the site’s participation in the study for reasonable cause. Breaking of the masked treatment codes will be done after locking the database. 10.5.1 Follow-up of subjects after study participation has ended

Clinical Study Termination. The Study Sponsor reserves the right to close the investigational site or terminate the study in its entirety at any time, for reasonable cause. If the clinical study is prematurely terminated or suspended by the Study Sponsor: • The Study Sponsor must: o Immediately notify the Investigator(s) and subsequently provide instructions for study termination. o Inform the Investigator and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension, as applicable. • The Investigator must: o Promptly notify the IRB IRB/IEC of the termination or suspension and of the reasons. o Provide subjects with recommendations for post-study treatment options as needed. The Investigator may terminate a the site’s participation in the study for reasonable cause. 10.5.1 Follow-up of subjects after study participation has ended

Clinical Study Termination. The Study Sponsor study sponsor reserves the right to close the investigational site or terminate the study in its entirety at any time, for reasonable cause. If the clinical study is prematurely terminated or suspended by the Study Sponsorstudy sponsor: • The Study Sponsor study sponsor must: o Immediately notify the Investigator(sinvestigator(s) and subsequently provide instructions for study termination. o Inform the Investigator investigator and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension, as applicable. • The Investigator investigator must: o Promptly notify the IRB of the termination or suspension and of the reasons. o Provide subjects with recommendations for post-study poststudy treatment options as needed. The Investigator investigator may terminate a site’s participation in the study for reasonable cause.

Clinical Study Termination. The Study Sponsor study sponsor reserves the right to suspend or close the investigational site or suspend or terminate the study in its entirety at any time, for reasonable cause. If the clinical study is prematurely terminated or suspended by the Study Sponsorstudy sponsor: • The Study Sponsor study sponsor must: o Immediately notify the Investigator(sinvestigator(s) and subsequently provide instructions for study termination. o Inform the Investigator investigator and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension, as applicable. • The Investigator investigator must: o Promptly notify the IRB IRB/IEC of the termination or suspension and of the reasons. o Provide subjects with recommendations for post-study treatment options as needed. The Investigator investigator may terminate a the site’s participation in the study for reasonable cause. Breaking of the masked treatment codes will be done after locking the database. 10.5.1 Follow-up of subjects after study participation has ended

Clinical Study Termination. The Study Sponsor reserves the right to close the investigational site or terminate the study in its entirety at any time, for reasonable cause. If the clinical study is prematurely terminated or suspended by the Study Sponsor: Sponsor:‌‌‌‌ • The Study Sponsor must: o Immediately notify the Investigator(s) and subsequently provide instructions for study termination. o Inform the Investigator Investigator(s) and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension, as applicable. • The Investigator must: o Promptly notify the IRB of the termination or suspension and of the reasons. o Provide subjects with recommendations for post-study treatment options as needed. The Investigator may terminate a site’s participation in the study for reasonable cause.

Clinical Study Termination. The Study Sponsor reserves the right to close the investigational site or terminate the study in its entirety at any time, for reasonable cause. If the clinical study is prematurely terminated or suspended by the Study Sponsor: • The Study Sponsor must: o Immediately notify the Investigator(s) and subsequently provide instructions for study termination. o Inform the Investigator Investigator(s) and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension, as applicable. • The Investigator Investigator(s) must: o Promptly notify the IRB IRB/IEC of the termination or suspension and of the reasons. o Provide subjects with recommendations for post-study treatment options as needed. The Investigator may terminate a the site’s participation in the study for reasonable cause.

Clinical Study Termination. The Study Sponsor reserves the right to close the investigational site or terminate the study in its entirety at any time, for reasonable cause. If the clinical study is prematurely terminated or suspended by the Study Sponsor: • The Study Sponsor must: o Immediately notify the Investigator(s) and subsequently provide instructions for study termination. o Inform the Investigator and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension, as applicable. • The Investigator must: o Promptly notify the IRB IRB/IEC of the termination or suspension and of the reasons. o Provide subjects with recommendations for post-study treatment options as needed. The Investigator may terminate a the site’s participation in the study for reasonable cause.

Clinical Study Termination. The Study Sponsor reserves the right to close the investigational site or terminate the study in its entirety at any time, for reasonable cause. If the clinical study is prematurely terminated or suspended by the Study Sponsor: • The Study Sponsor must: o Immediately notify the Investigator(s) and subsequently provide instructions for study termination. termination.‌‌‌‌‌ o Inform the Investigator and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension, as applicable. • The Investigator must: o Promptly notify the IRB of the termination or suspension and of the reasons. o Provide subjects with recommendations for post-study treatment options as needed. The Investigator may terminate a site’s participation in the study for reasonable cause.